Hanmi Pharm "Poziotinib, Twice-Daily Dosing Improves Safety and Tolerability"

AACR Announces Partner Company Spectrum

[Asia Economy Reporter Kim Ji-hee] Hanmi Pharmaceutical announced on the 14th that its partner Spectrum presented additional clinical data of its anticancer drug 'Poziotinib' at the American Association for Cancer Research (AACR), held online until the 15th.

In this presentation, Spectrum disclosed data from a study administering Poziotinib to non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) exon 20 insertion mutations. According to Spectrum, twice-daily dosing (BID) improved tolerability and reduced discontinuation rates compared to once-daily dosing (QD). Additionally, grade 3 or higher adverse events continuously decreased, and antitumor activity was confirmed.

This data is preliminary from 'Cohort 5' of the global clinical trial named ZENITH 20.

Fran?ois Revel, Chief Medical Officer (CMO) of Spectrum, stated, "Among various dosing regimens in different EGFR and HER2 Exon 20 mutant non-small cell lung cancer cohorts, the group receiving 8 mg twice daily (BID) showed the best efficacy," adding, "The confirmed improved therapeutic effect along with a reduced rate of side effects is very encouraging."

This content was produced with the assistance of AI translation services.